Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

Updated 06/21/2024

Status Completed

Clinical Trial Summary

Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid

Clinical Trial Details

NCT number	NCT05007860
Study type	Observational
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase
Start date	July 16, 2020
Completion date	June 30, 2023

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05665530` - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies	Phase 1
	Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
	Recruiting	`NCT04116437` - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment	Phase 2
	Withdrawn	`NCT04665115` - Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	Phase 2
	Completed	`NCT02268851` - A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL	Phase 1
	Recruiting	`NCT05003141` - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Phase 1
	Completed	`NCT03128359` - High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant	Phase 2
	Recruiting	`NCT04458610` - Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 2
	Completed	`NCT03041636` - Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2
	Recruiting	`NCT05294731` - Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader	Phase 1/Phase 2
	Active, not recruiting	`NCT04657094` - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia	Phase 2
	Recruiting	`NCT05876923` - The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients	N/A
	Completed	`NCT04748185` - Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
	Completed	`NCT02652715` - Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	N/A
	Recruiting	`NCT05643235` - Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors	N/A
	Completed	`NCT00090090` - Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 2
	Recruiting	`NCT05322733` - Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL	Phase 2